Novo’s record profit from obesity drugs has given the Foundation a war chest to fund its philanthropic grants, although ...

The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and cardiovascular ...